Catheter Associated Urinary Tract Infections (UTI) Treatment Market

Catheter Associated Urinary Tract Infections Treatment Market Outlook (2023 to 2033)

According to Future Market Insights research, during the projected period, the global Catheter Associated Urinary Tract Infections Treatment Market is expected to grow at a CAGR of 3.0%.

The market value is projected to increase from USD 1.31 Billion in 2023 to USD 1.76 Billion by 2033. The catheter associated urinary tract infections treatment market was valued at USD 1.26 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 3.9% in 2023.

Attributes	Details
Market Size (2023)	USD 1.31 Billion
Projected Market Value (2033)	USD 1.76 Billion
Global Market Growth Rate (2023 to 2033)	3.0% CAGR
Market Share of Top 5 Countries	52.1%

As assessed by Future Market Insights, among the drug type, quinolones held a market share of around 37.6% in the global market, in 2022. In 2022, the catheter associated urinary tract infections treatment market sales accounted for a revenue share of 72.3% in the global complicated UTI market, which was valued at around USD 1.8 Billion.

Sales Analysis of Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 4.1% in the last 5 years from 2017 to 2022.

Catheter associated urinary tract infections (CAUTIs) are common complications associated with use of the catheters. Elderly individuals are more susceptible to UTIs due to weakened immune systems, and urinary retentions.

Moreover, individuals with compromised immune systems such as those with diabetics, or undergoing immunosuppressive therapy are at increased risk of UTIs.

These infections may also reoccur more frequently due to the body’s reduced ability to fight off the infection.

• According to the National Library of Medicine - 2019, Urinary tract infections (UTIs) are the most common outpatient infections, with a lifetime incidence of 50−60% in adult women.
• According to the National Library of Medicine - 2019, In younger women, increased sexual activity is a major risk factor for UTIs and recurrence within 6 months is common.

The growth of catheter associated urinary tract infections treatment market is due to the growing number of UTIs and recurrent UTIs. This has led to a higher demand for effective treatment choices.

What are the Factors Influencing the Demand for Catheter Associated Urinary Tract Infections Treatment?

The increasing prevalence of CAUTIs worldwide can be attributed to a variety of factors, including prolonged catheter use, inadequate catheter care and hygiene and other factors.

Patients may require catheterization for a prolonged time due to various medical conditions. Prolonged catheter use increases the opportunity for bacteria to colonise the urinary tract and cause infection. Proper maintenance and care of the urinary catheters are essential for the reduction of the infection.

Hence, the global catheter associated urinary tract infections treatment market is been driven by the high prevalence and incidence rate of the disease worldwide.

Can the Market Growth Be Affected in Any Way?

The demand for new treatment arises from the need to address antibiotic-resistant CAUTIs. As bacteria become resistant to traditional antibiotics, it becomes harder to treat these infections efficiently.

This increases the risk of the implication and prolonged hospital stays for patients and adds a financial burden on the healthcare system due to the increased cost of treating drug-resistant infections.

• According to a study conducted by the University of Minnesota on March 22, 2023, it indicates that pathogens that cause catheter-associated urinary tract infections (CAUTIs) are more resistant to antibiotics than pathogens that do not cause CAUTIs.

• Based on research conducted by the University of Minnesota on March 22 2023, the rate of resistance to commonly prescribed antibiotics such as ciprofloxacin, norfloxacin, and trimethoprim-sulfamethoxazole ranges between 13 and 31 percent.

The prevalence of antibiotic-resistant CAUTIs is a significant concern as it limits the effectiveness of traditional antibiotic therapy. Moreover, the development of new antibiotics is slow and costly, and the pipeline for novel antibiotics is relatively dry. Moreover, this can be a significant factor affecting the growth of the CAUTIs market.

Country-wise Insights

What Factors are likely to drive the USA Market Forward?

The USA accounted for around 18.2% market share in the global market in 2022. The USA market’s growth is expected to rise at an overall CAGR of 2.2% over the forecast period.

Urinary tract infection is one of the most frequent infectious diseases caused by bacteria. A complicated urinary tract infection can affect anyone, regardless of gender or age, and they are caused by anatomical or functional abnormalities in the urinary system.

• According to an article published by the National Library of Medicine on May 2, 2019, between 50% and 60% of adult women will encounter at least one UTI in their lifetime, while about 10% of postmenopausal women reported having a UTI in the previous year.

An increase in chronic illness such as diabetes, and kidney disease, such as renal failure and bladder cancer, is driving the usage of catheters and other drainage devices among patients and the increased use of indwelling use of urinary catheters is the attributing factor in the rise of complicated UTIs. Complicated UTIs are generally more challenging to treat compared to uncomplicated UTIs, as they are associated with more severe symptoms and have a higher risk of complication.

These are the major factors that help the market grow exponentially in the USA, region.

Why India Market is Dominating Global Urinary Tract Infections Treatment Market?

The India market held around 10.2 % market share of the global market in 2022.

The large patient population in India is one of the reasons why the Indian market has a significant presence in the global catheter associated urinary tract infections treatment market.

With such a large population, the incidence and prevalence of CAUTIs are also higher.

• According to an article published by the Department of Economic and Social Affairs on April 2023, the current population of India is about 1.42 Billion.

Since CAUTI is a common healthcare-associated infection, the large patient population in India creates a high demand for CAUTIs treatment.

What are the Factors Contributing to High Demand for Catheter Associated Urinary Tract Infections Treatment in China?

China held a market share of about 9.5% of the global market in 2022.

The Chinese government to improve healthcare outcomes and reduce healthcare-associated infections, including CAUTIs, has implemented several measures and programs.

The promotion of awareness and education regarding infection prevention measures is one significant initiative. The aim is to increase awareness among healthcare providers and patients about the risk associated with CAUTIs and the importance of preventing the infection.

The government provides training and education to healthcare providers to enhance their knowledge and skills in preventing CAUTIs. Additionally, they focus on this effort. In addition, supporting the adoption of infection prevention measures in healthcare facilities. China is in demand for the market of catheter-associated urinary tract infections.

Category-wise Insights

Why Drug Type is leading in the Global Market?

The Quinolones sub-segment held around 37.6% share of the global market in 2022 within the drug type.

Quinolones have a broad-spectrum antimicrobial activity. In addition, Gram-negative organism commonly causes CAUTIs, and quinolones have demonstrated efficacy against these pathogens. In addition, quinolones have the ability to achieve high concentration in the urine, which is desirable for treating urinary tract infections.

Quinolones also have good penetration in the tissue of the urinary tract, including the bladder wall, renal parenchyma and prostate gland.

They are also available in both oral and intravenous formulations providing convenience and flexibility in the treatment of CAUTIs.

Which Indication Type has a higher share within the Global Market?

The Asymptomatic CAUTI (Bacteriuria) segment held around 58.9% share of the total market in 2022 within the indication type.

In comparison to symptomatic CAUTIs, asymptomatic CAUTIs are more common. Many patients with urinary catheters may not exhibit common infection symptoms, such as fever or pain, making it difficult to detect these infections without specialized testing.

The greater prevalence of asymptomatic CAUTIs contributes to its dominant position in the indication type segment.

Which Service Provider Propels the Global Sales in the Market?

Retail pharmacies hold a share of about 43.2% in 2022, within the global market.

Medication used in the treatment of CAUTIs is mainly distributed through retail pharmacies, which serve as the main distribution hubs. To ensure that patients have access to necessary antibiotics and other relevant drugs, they make sure that these medications are available.

In retail settings, pharmacists and pharmacy staff offer education and counselling to patients about the correct use of medication for CAUTIs. These are the services provided by them. Retail pharmacies offer a variety of over-the-counter products that can assist in managing CAUTIs in addition to the prescribed medication.

Competition Landscape

The treatment market for catheter-associated urinary tract infections treatment is competitive. In addition to expanding their presence in emerging markets through new partnerships and merger acquisitions, market leaders are concentrating on the introduction of technologically advanced products.

The competitive environment includes an analysis of a handful of global and local corporations that control the majority of the market share. In addition to acquisitions, mergers, and partnerships with key market participants.

Some key instances of development include:

• In June 2019, it was announced by Merck that a definitive agreement has been entered into with Tilos Therapeutics for the development of drugs to treat cancer, fibrosis, and autoimmune diseases.
• In November 2018, Allergan announced that the FDA has accepted the Supplemental New Drug Application for Avycaz to treat patients with Complicated Urinary Tract Infections (CUTI) and Complicated Intra-Abdominal Infections (CIAI).

Similarly, the team at Future Market Insights has tracked recent developments related to companies in the catheter associated urinary tract infections treatment market, which are available in the full report.

Catheter Associated Urinary Tract Infections Treatment Industry Report Scope

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	USD Million for Value
Key Regions Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa.
Key Countries Covered	USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Northern Africa, and South Africa
Key Market Segments Covered	Drug Type, Indication, Distribution Channel and Region
Key Companies Covered	Pfizer Inc.; Merck & Co., Inc.; GlaxoSmithKline (GSK); AstraZeneca; Bayer AG; Johnson & Johnson; Novartis International AG; Sanofi; Roche Holding AG; Eli Lilly and Company; Bristol-Myers Squibb Company; Abbott Laboratories; Astellas Pharma Inc.; Boehringer Ingelheim; Daiichi Sankyo Company, Limited; Gilead Sciences, Inc.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Lupin Limited
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Key Segments Covered in Urinary Tract Infections Treatment Industry Research

By Drug Type:

• Penicillin & Combinations
  • Amoxicillin
  • Amoxicillin+ Clavulanate Potassium
  • Others
• Quinolones
  • Ciprofloxacin
  • Levofloxacin
  • Nalidixic acid
  • Norfloxacin
  • Others
• Cephalosporin
  • Ceftriaxone
  • Cefuroxime
  • Cefixime
  • Cephalexin
• Aminoglycoside Antibiotics
  • Amikacin
  • Gentamicin
• Sulphonamides (Sulfamethoxazole +Trimethoprim)
• Azoles and Amphotericin B
• Tetracycline (Doxycycline)
• Nitrofurans (Nitrofurantoin)
• Other

By Indication Type:

• Asymptomatic CAUTI (Bacteriuria)
• Symptomatic CAUTI (Bacteremic)

By Distribution Channel:

• Hospital Pharmacies
• Gynaecology and Urology Clinics
• Drug Stores
• Retail Pharmacies
• Online Drug Stores

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the Catheter Associated Urinary Tract Infections Treatment Market Size in 2023?

The market is expected to be valued at USD 1.31 billion in 2023.

Who are the Prominent Catheter Associated Urinary Tract Infections Treatment Market Players?

AstraZeneca, Bayer AG, and Sanofi are the key market players.

What Factors are likely to Drive the United States Market Forward?

Increased prevalence of chronic illnesses like diabetes drives catheter usage.

Which Service Provider Propels the Global Sales in the Market?

Retail pharmacies hold a share of about 43.2% in 2022.

What is the Projected Size of the Market by 2033?

The market is estimated to reach USD 1.76 billion by 2033.